Fasting serum fructose is associated with metabolic dysfunction‐associated fatty liver disease: A prospective study
Hepatology Research · 2023-06 · 53 (6) · 479-488
DOI: 10.1111/hepr.13888 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology Research, online erschienen am 25.02.2023. Verfasst von Yujuan Fan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Aim
The association between sugar‐sweetened beverages and metabolic disorders has been well studied. However, it has not been determined whether fasting serum fructose is associated with metabolic dysfunction‐associated fatty liver disease (MAFLD).
Methods
Participants were enrolled from 2011 to 2012 in Shanghai. Fasting serum fructose concentration was measured with a validated liquid chromatography–tandem mass spectrometry method.
Results
A total of 954 participants without diabetes were included. They were followed for an average of 3.5 years. A total of 320 (33.5%) participants had MAFLD at baseline. With the increase in fasting serum fructose level by quartile, the MAFLD prevalence was increased by 27.0%, 25.0%, 37.4%, and 44.5%, respectively ( p < 0.001). Each SD increase in fasting serum fructose level was associated with a 60% increased risk of MAFLD (odds ratio 1.60; 95% confidence interval [CI], 1.36–1.88; p < 0.001). Fasting serum fructose levels were more closely associated with four components of MAFLD (hepatic steatosis, prediabetes, insulin resistance, and low high‐density lipoprotein). We built a diagnostic model named the fructose fat index (FFI). The area under the receiver operating characteristic curve of the FFI was 0.879 (95% CI, 0.850–0.908) in the derivation cohort and 0.827 (95% CI, 0.776–0.878) in the validation cohort. Subsequent prospective studies found that the incidence risk of MAFLD was 2.26 times higher in the high‐fructose group than in the low‐fructose group among female participants (95% CI, 1.46–3.49; p < 0.001).
Conclusion
Fasting serum fructose concentration, which mostly reflects endogenous fructose, was associated with a higher risk of MAFLD. The FFI derived from fasting serum fructose could be used to predict MAFLD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Endocrinology and Metabolism, Minhang Hospital, Fudan University, Shanghai, China.
- General Practice Department, Affiliated Kunshan Hospital of Jiangsu University, Suzhou, China.
- Department of Endocrinology and Metabolism, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
ORCID-Profile: Yujuan Fan
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Fan, Y., Zhang, Y., Chen, C., Ying, Z., Su, Q., Li, X., & Chen, Y. (2023). Fasting serum fructose is associated with metabolic dysfunction‐associated fatty liver disease: A prospective study. Hepatology Research, 53(6), 479-488. https://doi.org/10.1111/hepr.13888
Vancouver
Fan Y, Zhang Y, Chen C, Ying Z, Su Q, Li X, et al. Fasting serum fructose is associated with metabolic dysfunction‐associated fatty liver disease: A prospective study. Hepatology Research. 2023;53(6):479-488. doi:10.1111/hepr.13888
BibTeX
@article{Fan2023,
author = {Fan, Yujuan and Zhang, Yuecheng and Chen, Congling and Ying, Zhen and Su, Qing and Li, Xiaoying and Chen, Ying},
title = {Fasting serum fructose is associated with metabolic dysfunction‐associated fatty liver disease: A prospective study},
journal = {Hepatology Research},
year = {2023},
volume = {53},
number = {6},
pages = {479--488},
doi = {10.1111/hepr.13888}
}
EUVIMED